Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare OTCMKTS:CVSINASDAQ:DRRXOTCMKTS:LTUSNASDAQ:SLGL On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeCVSICV Sciences$0.03+9.3%$0.03$0.02▼$0.09$5.45M0.47220,526 shs13,562 shsDRRXDURECT$0.62-3.9%$0.63$0.48▼$1.84$19.09M0.5985,351 shs62,479 shsLTUSLotus Pharmaceuticals$0.01-12.7%$0.01$0.00▼$0.01$18.25M-2.4860,362 shs627 shsSLGLSol-Gel Technologies$7.52+9.0%$6.83$3.34▼$16.50$20.95M1.132,904 shs102,998 shs7 Energy Stocks to Buy and Hold ForeverWith the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceCVSICV Sciences0.00%+16.14%-1.34%-10.61%-65.13%DRRXDURECT0.00%+13.68%-0.42%-28.49%-60.58%LTUSLotus Pharmaceuticals0.00%+38.00%+30.19%-12.66%+130.00%SLGLSol-Gel Technologies0.00%+3.87%-1.96%+35.23%-3.60%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationCVSICV Sciences0.7364 of 5 stars0.05.00.00.02.80.00.0DRRXDURECT1.3351 of 5 stars0.03.00.04.43.80.00.0LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies3.0048 of 5 stars3.55.00.00.03.01.70.0Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceCVSICV Sciences 0.00N/AN/AN/ADRRXDURECT 2.00HoldN/AN/ALTUSLotus Pharmaceuticals 0.00N/AN/AN/ASLGLSol-Gel Technologies 3.00Buy$40.00431.91% UpsideCurrent Analyst Ratings BreakdownLatest CVSI, SLGL, LTUS, and DRRX Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/27/2025DRRXDURECTHC WainwrightSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingNeutral ➝ Neutral(Data available from 6/15/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookCVSICV Sciences$16M0.34$0.02 per share1.75$0.02 per share1.48DRRXDURECT$1.86M10.29N/AN/A$0.50 per share1.23LTUSLotus PharmaceuticalsN/AN/AN/AN/AN/AN/ASLGLSol-Gel Technologies$12.10M1.73N/AN/A$1.67 per share4.50Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateCVSICV Sciences$3.10M-$0.01N/A∞N/A-16.24%-101.85%-29.04%N/ADRRXDURECT-$27.62M-$0.15N/AN/AN/A-198.58%-300.62%-65.17%8/5/2025 (Estimated)LTUSLotus Pharmaceuticals-$20KN/A0.00∞N/AN/AN/AN/AN/ASLGLSol-Gel Technologies-$27.24M-$4.70N/AN/AN/A-81.75%-27.17%-22.49%8/14/2025 (Estimated)Latest CVSI, SLGL, LTUS, and DRRX EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/23/2025Q1 2025SLGLSol-Gel TechnologiesN/A-$3.20N/A-$3.20N/A$1.03 million3/26/2025Q4 2024DRRXDURECT$0.06-$0.06-$0.12$0.24$6.91 million$2.30 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthCVSICV SciencesN/AN/AN/AN/AN/ADRRXDURECTN/AN/AN/AN/AN/ALTUSLotus PharmaceuticalsN/AN/AN/AN/AN/ASLGLSol-Gel TechnologiesN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioCVSICV SciencesN/A1.100.28DRRXDURECTN/A0.710.60LTUSLotus PharmaceuticalsN/AN/AN/ASLGLSol-Gel TechnologiesN/A5.815.81Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipCVSICV SciencesN/ADRRXDURECT28.03%LTUSLotus PharmaceuticalsN/ASLGLSol-Gel Technologies26.18%Insider OwnershipCompanyInsider OwnershipCVSICV Sciences3.80%DRRXDURECT3.20%LTUSLotus PharmaceuticalsN/ASLGLSol-Gel Technologies66.51%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableCVSICV Sciences70184.79 million182.39 millionNot OptionableDRRXDURECT8031.04 million30.05 millionOptionableLTUSLotus Pharmaceuticals2302.64 billionN/ANot OptionableSLGLSol-Gel Technologies502.79 million9.33 millionOptionableCVSI, SLGL, LTUS, and DRRX HeadlinesRecent News About These CompaniesSol Gel Tech Stock Price HistoryJune 1, 2025 | investing.comSol-Gel Technologies Ltd.: Sol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | finanznachrichten.deSol-Gel Stock Tumbles Over Underwhelming Q1 Earnings: Retail Stays PessimisticMay 23, 2025 | msn.comSol-Gel Technologies Reports Q1 2025 Financial Results and Increased R&D ExpensesMay 23, 2025 | quiverquant.comSol-Gel Reports First Quarter 2025 ResultsMay 23, 2025 | globenewswire.comInsider Buying: Sol-Gel Technologies CEO & Executive Chairman Bought US$98k Of SharesMay 3, 2025 | uk.finance.yahoo.comThis Sol-Gel Technologies Insider Increased Their Holding In The Last YearMay 2, 2025 | finance.yahoo.comSol-Gel Announces Reverse Share SplitMay 1, 2025 | globenewswire.comSol-Gel, Mayne Pharma enter product purchase agreementApril 17, 2025 | markets.businessinsider.comSol-Gel Technologies Ltd.: Sol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY and TWYNEO in the U.S.April 17, 2025 | finanznachrichten.deSol-Gel and Mayne Pharma Announce the Purchase of EPSOLAY® and TWYNEO® in the U.S.April 17, 2025 | globenewswire.comGlobal Sol-Gel Coatings Market Research 2025-2035: Competitive Landscape, Functional Properties and Applications, End-users, Technology Fundamentals, Overview and Growth AnalysisApril 7, 2025 | globenewswire.comSol-Gel Technologies Approves Reverse Share Split and Compensation Policy RenewalApril 1, 2025 | tipranks.comSLGL Gears Up to Report Q4 Earnings: Here's What You Should KnowFebruary 25, 2025 | zacks.comIs Sol-Gel Technologies (NASDAQ:SLGL) In A Good Position To Deliver On Growth Plans?February 7, 2025 | finance.yahoo.comSol Gel Technologies Ltd (SLGL) Stock Trading RecapDecember 26, 2024 | bovnews.comIs SolGel Technologies (SLGL) a Great Value Stock Right Now?December 25, 2024 | zacks.comSol-Gel Technologies Reports Strong Q3 2024 ResultsNovember 21, 2024 | markets.businessinsider.comSol-Gel announces 180-day extension to regain compliance with NasdaqNovember 21, 2024 | markets.businessinsider.comSolGel Technologies (SLGL) Upgraded to Buy: Here's What You Should KnowNovember 20, 2024 | zacks.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeCVSI, SLGL, LTUS, and DRRX Company DescriptionsCV Sciences OTCMKTS:CVSI$0.03 +0.00 (+9.26%) As of 06/13/2025 02:05 PM EasternCV Sciences, Inc. develops, manufactures, markets, and sells herbal supplements and hemp-based cannabidiol (CBD) in North America. It operates in two segments, Consumer Products and Specialty Pharmaceutical. The company offers its products under the PlusCBD, ProCBD, HappyLane, CVAcute, CVDefense, and PlusCBD Pet brands in the health care market sector, including nutraceutical, beauty care, specialty foods, and pet products through its websites, elect distributors, brick and mortar retailers, and select e-tailers. It is also developing cannabinoids intended to treat medical indications, including CVSI-007 that combines CBD and nicotine for the treatment of smokeless tobacco use and addiction. The company was formerly known as CannaVest Corp. and changed its name to CV Sciences, Inc. in January 2016. CV Sciences, Inc. was incorporated in 2010 and is based in San Diego, California.DURECT NASDAQ:DRRX$0.62 -0.03 (-3.91%) As of 06/13/2025 04:00 PM EasternDURECT Corporation, a biopharmaceutical company, develops medicines based on its epigenetic regulator program. The company's lead product larsucosterol (DUR-928), an endogenous, orally bioavailable small molecule that is in Phase IIb clinical trial to play a regulatory role in lipid metabolism, stress and inflammatory responses, and cell death and survival to treat alcohol-associated hepatitis, as well as completed Phase Ib clinical trial to treat patients with nonalcoholic steatohepatitis. It also offers ALZET product line that consists of osmotic pumps and accessories used for research in mice, rats, and other laboratory animals. In addition, the company offers POSIMIR, a post-surgical pain product to deliver bupivacaine over three days in adults; and Methydur to treat attention deficit hyperactivity disorder. It markets and sells its ALZET lines through direct sales force in the United States, as well as through a network of distributors in other countries. The company has strategic collaboration and other agreements with Virginia Commonwealth University Intellectual Property Foundation; Indivior UK Ltd.; and Innocoll Pharmaceuticals Limited. DURECT Corporation was incorporated in 1998 and is headquartered in Cupertino, California.Lotus Pharmaceuticals OTCMKTS:LTUS$0.0069 0.00 (-12.66%) As of 06/13/2025 11:39 AM EasternLotus Pharmaceuticals, Inc. does not have significant operations. Previously, it was engaged in the development, manufacture, and sale of pharmaceuticals in the People's Republic of China. The company is based in Nashville, Tennessee.Sol-Gel Technologies NASDAQ:SLGL$7.52 +0.62 (+8.99%) Closing price 06/13/2025 04:00 PM EasternExtended Trading$7.36 -0.15 (-2.06%) As of 06/13/2025 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Sol-Gel Technologies Ltd., together with its subsidiary Sol-Gel Technologies Inc., develops topical dermatological drugs for patients with severe skin conditions in Israel. The company offers Twyneo, a once-daily, non-antibiotic topical cream for the treatment of acne vulgaris; and Epsolay, a once-daily topical cream for the treatment of papulopustular (subtype II) rosacea. It also develops SGT-610 that is in Phase 3 clinical trials for the treatment of Gorlin Syndrome; and SGT-210, which has completed Phase I clinical trial, to treat rare hyperkeratinization disorders, such as Darier, PC, PPK, Olmsted, etc. In addition, the company is also involved in the development of generic topical dermatological drug products. It has collaboration with Padagis Israel Pharmaceuticals Ltd; and license agreements with Galderma Holding SA and Searchlight Pharma Inc. Sol-Gel Technologies Ltd. was incorporated in 1997 and is headquartered in Ness Ziona, Israel. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 06/09 - 06/13 Alphabet Enters a Bull Market: Is It Time to Buy? Ouster Soars 27% as DoD Grants First 3D LiDAR Approval for Drones Super Micro Computer Stock: 2 Levels Smart Money Is Watching Intel's Price Spikes: Noise, or the First Notes of a Turnaround? IBM Up 10 Days in a Row: What’s Driving the Winning Streak? SoFi Stock’s Next Test: Can It Justify Its Premium Valuation? Ignore the Noise—Samsara Stock Is Still a Strong Buy Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
